{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:01:36Z","timestamp":1786460496796,"version":"build-2736575974"},"reference-count":110,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012]]},"DOI":"10.11124\/jbisrir-2012-31","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T11:21:51Z","timestamp":1468495311000},"page":"2593-2657","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic factors for risk stratification of adult cancer patients with chemotherapy-induced febrile neutropenia: a systematic review and meta-analysis"],"prefix":"10.11124","volume":"10","author":[{"given":"Yee Mei","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Lockwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"12","key":"R1-1-20210207","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/0959-8049(95)00292-8","article-title":"An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients.","volume":"31A","author":"Viscoli","year":"1995","journal-title":"Eur J Cancer"},{"issue":"suppl 4","key":"R2-1-20210207","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/41.suppl_4.1","article-title":"Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies.","volume":"41","author":"Bow","year":"1998","journal-title":"J Antimicrob Chemother"},{"issue":"1-2","key":"R3-1-20210207","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/10428199309148512","article-title":"Predicting neutropenia after chemotherapy for lymphoma.","volume":"9","author":"Watkins","year":"1993","journal-title":"Leuk Lymphoma"},{"issue":"3-4","key":"R4-1-20210207","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3109\/10428190009089435","article-title":"A Predictive Model for Life-Threatening Neutropenia and Febrile Neutropenia after the First Course of CHOP Chemotherapy in Patients with Aggressive Non-Hodgkins Lymphoma.","volume":"37","author":"Intragumtornchai","year":"2000","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"R5-1-20210207","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0889-8588(05)70275-6","article-title":"Aging and cancer in America: demographic and epidemiologic perspectives.","volume":"14","author":"Yancik","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"R6-1-20210207","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","article-title":"Chemotherapy-induced neutropenia.","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer"},{"issue":"16","key":"R7-1-20210207","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jnci\/90.16.1205","article-title":"C., Wood WC, Weiss RB, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer.","volume":"90","author":"Budman","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"R9-1-20210207","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"R10-1-20210207","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.critrevonc.2004.01.001","article-title":"The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.","volume":"50","author":"Lyman","year":"2004","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"R12-1-20210207","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1086\/313642","article-title":"Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor.","volume":"30","author":"Kuritzkes","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"Supplement 1","key":"R13-1-20210207","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1086\/383050","article-title":"Management of fever in neutropenic patients with different risks of complications.","volume":"39","author":"Klastersky","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"2","key":"R15-1-20210207","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","article-title":"Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.","volume":"64","author":"Bodey","year":"1966","journal-title":"Ann Intern Med"},{"issue":"3","key":"R16-1-20210207","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(84)90661-2","article-title":"Neutropenia, fever, and infection.","volume":"76","year":"1984","journal-title":"The American Journal of Medicine"},{"issue":"6","key":"R17-1-20210207","first-page":"730","article-title":"2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis.","volume":"34","author":"Hughes","year":"2002","journal-title":"Article"},{"issue":"3","key":"R18-1-20210207","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/infdis\/161.3.381","article-title":"From the Infectious Disease Society of America: Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever.","volume":"161","author":"Hughes","year":"1990","journal-title":"The Journal of Infectious Diseases"},{"key":"R19-1-20210207","first-page":"S158","article-title":"Sepsis in neutropenia - Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).","volume":"82","author":"Schiel","year":"2003","journal-title":"Ann Hematol"},{"key":"R20-1-20210207","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1093\/infdis\/130.Supplement.S24","article-title":"Significance of pseudomonas aeruginosa in the patient with leukemia or lymphoma.","volume":"130","author":"Schimpff","year":"1974","journal-title":"The Journal of Infectious Diseases"},{"issue":"5","key":"R21-1-20210207","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/archinte.1975.00330050089015","article-title":"Clinical presentation of infection in granulocytopenic patients.","volume":"135","author":"Sickles","year":"1975","journal-title":"Arch Intern Med"},{"key":"R22-1-20210207","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00277-003-0766-2","article-title":"Diagnosis and treatment of documented infections in neutropenic patients.","volume":"82","author":"Buchheidt","year":"2003","journal-title":"Ann Hematol"},{"issue":"2","key":"R23-1-20210207","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1086\/514550","article-title":"Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials.","volume":"25","author":"Elting","year":"1997","journal-title":"Clin Infect Dis"},{"issue":"3","key":"R24-1-20210207","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1200\/JCO.1998.16.3.1179","article-title":"Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis.","volume":"16","author":"Engels","year":"1998","journal-title":"J Clin Oncol"},{"issue":"1","key":"R25-1-20210207","doi-asserted-by":"crossref","first-page":"979","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00008","article-title":"Meta-Analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.","volume":"142","author":"Gafter-Gvili","year":"2005","journal-title":"Ann Intern Med"},{"issue":"18","key":"R26-1-20210207","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJM199305063281808","article-title":"Management of fever in patients with cancer and treatment-induced neutropenia.","volume":"328","author":"Pizzo","year":"1993","journal-title":"N Engl J Med"},{"issue":"5","key":"R27-1-20210207","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/annonc\/mdq442","article-title":"Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology.","volume":"22","author":"Penack","year":"2011","journal-title":"Ann Oncol"},{"issue":"Supplement 1","key":"R28-1-20210207","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1093\/clinids\/19.Supplement_1.S49","article-title":"Infections due to resistant candida species in patients with cancer who are receiving chemotherapy.","volume":"19","author":"Wingard","year":"1994","journal-title":"Clin Infect Dis"},{"issue":"17","key":"R29-1-20210207","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJM199404283301717","article-title":"Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia.","volume":"330","author":"Cometta","year":"1994","journal-title":"N Engl J Med"},{"issue":"3","key":"R31-1-20210207","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-2648.1996.tb00015.x","article-title":"An exploratory study of recipients perceptions of bone marrow transplantation.","volume":"23","author":"Tham","year":"1996","journal-title":"J Adv Nurs"},{"issue":"2","key":"R32-1-20210207","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.1365-2648.1999.01099.x","article-title":"Feelings of oncology patients about being nursed in protective isolation as a consequence of cancer chemotherapy treatment.","volume":"30","author":"Campbell","year":"1999","journal-title":"J Adv Nurs"},{"issue":"4","key":"R34-1-20210207","doi-asserted-by":"crossref","first-page":"557","DOI":"10.6004\/jnccn.2005.0031","article-title":"Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence.","volume":"3","author":"Lyman","year":"2005","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"3","key":"R35-1-20210207","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1078155208091249","article-title":"The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting.","volume":"14","author":"Tuffaha","year":"2008","journal-title":"Journal of Oncology Pharmacy Practice"},{"issue":"9","key":"R36-1-20210207","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1200\/JCO.1996.14.9.2511","article-title":"Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology.","volume":"14","author":"Bennett","year":"1996","journal-title":"J Clin Oncol"},{"issue":"6","key":"R37-1-20210207","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","article-title":"First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.","volume":"23","author":"Vogel","year":"2005","journal-title":"J Clin Oncol"},{"key":"R38-1-20210207","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1469-0691.2005.01138.x","article-title":"Current and emerging serious gram-positive infections.","volume":"11","author":"Menichetti","year":"2005","journal-title":"Clinical Microbiology and Infection"},{"issue":"6","key":"R39-1-20210207","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/clinids\/14.6.1201","article-title":"Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors.","volume":"14","author":"Elting","year":"1992","journal-title":"Clin Infect Dis"},{"issue":"12","key":"R40-1-20210207","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1001\/archinte.1988.00380120031007","article-title":"The medical course of cancer patients with fever and neutropenia: clinical identification of a low-risk subgroup at presentation.","volume":"148","author":"Talcott","year":"1988","journal-title":"Arch Intern Med"},{"issue":"3","key":"R42-1-20210207","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.leukres.2009.08.024","article-title":"The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease.","volume":"34","author":"Park","year":"2010","journal-title":"Leuk Res"},{"issue":"1","key":"R43-1-20210207","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1200\/JCO.1994.12.1.107","article-title":"Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule.","volume":"12","author":"Talcott","year":"1994","journal-title":"J Clin Oncol"},{"issue":"3","key":"R44-1-20210207","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0002-9343(99)80367-2","article-title":"Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial.","volume":"98","author":"Malik","year":"1995","journal-title":"The American Journal of Medicine"},{"issue":"1","key":"R45-1-20210207","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/dkh303","article-title":"Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials.","volume":"54","author":"Vidal","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"R46-1-20210207","first-page":"215","article-title":"The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies.","volume":"91","author":"Cherif","year":"2006","journal-title":"Haematologica"},{"issue":"1","key":"R47-1-20210207","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.bjc.6600993","article-title":"Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study.","volume":"89","author":"Innes","year":"2003","journal-title":"Br J Cancer"},{"issue":"Supplement 4","key":"R48-1-20210207","doi-asserted-by":"crossref","first-page":"S246","DOI":"10.1086\/427331","article-title":"Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia.","volume":"40","author":"Rolston","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R49-1-20210207","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1071\/AH10951","article-title":"A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment.","volume":"35","author":"Lingaratnam","year":"2011","journal-title":"Aust Health Rev"},{"key":"R52-1-20210207","doi-asserted-by":"crossref","first-page":"b375","DOI":"10.1136\/bmj.b375","article-title":"Prognosis and prognostic research: what, why, and how?","volume":"338","author":"Moons","year":"2009","journal-title":"BMJ"},{"key":"R53-1-20210207","doi-asserted-by":"crossref","first-page":"b604","DOI":"10.1136\/bmj.b604","article-title":"Prognosis and prognostic research: developing a prognostic model.","volume":"338","author":"Royston","year":"2009","journal-title":"BMJ"},{"key":"R56-1-20210207","doi-asserted-by":"crossref","first-page":"b605","DOI":"10.1136\/bmj.b605","article-title":"Prognosis and prognostic research: validating a prognostic model.","volume":"338","author":"Altman","year":"2009","journal-title":"BMJ"},{"issue":"9","key":"R57-1-20210207","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/heartjnl-2011-301246","article-title":"Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker.","volume":"98","author":"Moons","year":"2012","journal-title":"Heart"},{"issue":"4","key":"R58-1-20210207","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America.","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"6","key":"R60-1-20210207","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archinte.1962.03620240038007","article-title":"Gram-negative bacteremia: II. clinical, laboratory, and therapeutic observations.","volume":"110","author":"McCabe","year":"1962","journal-title":"Arch Intern Med"},{"issue":"9","key":"R61-1-20210207","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1002\/1097-0142(19940501)73:9<2296::AID-CNCR2820730910>3.0.CO;2-7","article-title":"Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study.","volume":"73","author":"Maschmeyer","year":"1994","journal-title":"Cancer"},{"issue":"11","key":"R63-1-20210207","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/1097-0142(19930601)71:11<3640::AID-CNCR2820711128>3.0.CO;2-H","article-title":"Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer.","volume":"71","author":"Rubenstein","year":"1993","journal-title":"Cancer"},{"issue":"suppl 5","key":"R65-1-20210207","doi-asserted-by":"crossref","first-page":"v252","DOI":"10.1093\/annonc\/mdq196","article-title":"Management of febrile neutropenia: ESMO clinical practice guidelines.","volume":"21","author":"De Naurois","year":"2010","journal-title":"Ann Oncol"},{"issue":"1b","key":"R66-1-20210207","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1445-5994.2010.02339.x","article-title":"Use of risk stratification to guide ambulatory management of neutropenic fever.","volume":"41","author":"Worth","year":"2011","journal-title":"Internal Medicine Journal"},{"issue":"8","key":"R67-1-20210207","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00520-004-0614-5","article-title":"Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.","volume":"12","author":"Uys","year":"2004","journal-title":"Support Care Cancer"},{"issue":"7","key":"R68-1-20210207","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00520-007-0347-3","article-title":"Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients.","volume":"16","author":"de Souza Viana","year":"2008","journal-title":"Support Care Cancer"},{"issue":"3","key":"R69-1-20210207","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/sj.bmt.1705561","article-title":"Risk factor analysis of blood stream infection and pneumonia in neutropenic patients after peripheral blood stem-cell transplantation.","volume":"39","author":"Meyer","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"R70-1-20210207","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jinf.2009.08.009","article-title":"A simple score to predict early death in adult cancer patients with bloodstream infections.","volume":"59","author":"Velasco","year":"2009","journal-title":"J Infect"},{"key":"R72-1-20210207","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3346\/jkms.2005.20.1.31","article-title":"Prognostic factors influencing infection-related mortality in patients with acute leukemia in Korea.","volume":"20","author":"Yoo","year":"2005","journal-title":"J Korean Med Sci"},{"issue":"1","key":"R73-1-20210207","first-page":"28","article-title":"Factors associated with severe sepsis: prospective study of 94 neutropenic febrile episodes. Hematology.","volume":"15","author":"Jeddi","year":"2010","journal-title":"Article"},{"issue":"7","key":"R74-1-20210207","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00520-010-0925-7","article-title":"Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?","volume":"19","author":"Paesmans","year":"2011","journal-title":"Support Care Cancer"},{"issue":"5","key":"R75-1-20210207","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1089\/15258160050196687","article-title":"Clinical and laboratory features predicting a favorable outcome and allowing early discharge in cancer patients with low-risk febrile neutropenia: a literature review.","volume":"9","author":"Castagnola","year":"2000","journal-title":"J Hematother Stem Cell Res"},{"issue":"5","key":"R76-1-20210207","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/bjc.2011.284","article-title":"Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients.","volume":"105","author":"Carmona-Bayonas","year":"2011","journal-title":"Br J Cancer"},{"issue":"4","key":"R77-1-20210207","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00277-006-0248-4","article-title":"Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia.","volume":"86","author":"Girmenia","year":"2007","journal-title":"Ann Hematol"},{"issue":"4","key":"R78-1-20210207","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ejim.2011.12.010","article-title":"Evaluation of transient hyperglycemia in non-diabetic patients with febrile neutropenia.","volume":"23","author":"Soysal","year":"2012","journal-title":"European Journal of Internal Medicine"},{"issue":"6-7","key":"R79-1-20210207","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3109\/00365548.2011.554855","article-title":"Elevated procalcitonin predicts Gram-negative sepsis in haematological patients with febrile neutropenia.","volume":"43","author":"Koivula","year":"2011","journal-title":"Scand J Infect Dis"},{"issue":"2","key":"R80-1-20210207","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/pbc.24158","article-title":"Biomarkers for risk stratification of febrile neutropenia among children with malignancy: A pilot study.","volume":"59","author":"Mian","year":"2012","journal-title":"Pediatric Blood Cancer"},{"issue":"8","key":"R81-1-20210207","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/0895-4356(88)90164-3","article-title":"Day hospital as an alternative to inpatient care for cancer patients: a random assignment trial.","volume":"41","author":"Mor","year":"1988","journal-title":"J Clin Epidemiol"},{"issue":"7290","key":"R82-1-20210207","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/bmj.322.7290.826","article-title":"Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial.","volume":"322","author":"Borras","year":"2001","journal-title":"BMJ"},{"issue":"4","key":"R83-1-20210207","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1191\/1078155201jp084oa","article-title":"Predictors for chemotherapy-related severe or febrile neutropenia: a review of the clinical literature.","volume":"7","author":"Wilson-Royalty","year":"2001","journal-title":"Journal of Oncology Pharmacy Practice"},{"issue":"7119","key":"R84-1-20210207","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.315.7119.1371","article-title":"Meta-analysis: potentials and promise.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"8","key":"R85-1-20210207","first-page":"207","article-title":"The JBI model of evidence-based healthcare.","volume":"3","author":"Pearson","year":"2005","journal-title":"International Journal of Evidence-Based Healthcare"},{"issue":"7306","key":"R86-1-20210207","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/bmj.323.7306.224","article-title":"Systematic reviews of evaluations of prognostic variables.","volume":"323","author":"Altman","year":"2001","journal-title":"BMJ"},{"issue":"6","key":"R87-1-20210207","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/0003-4819-144-6-200603210-00010","article-title":"Evaluation of the quality of prognosis studies in systematic reviews.","volume":"144","author":"Hayden","year":"2006","journal-title":"Ann Intern Med"},{"issue":"1","key":"R89-1-20210207","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/0163278702025001006","article-title":"To IPD or not to IPD? advantages and disadvantages of systematic reviews using individual patient data.","volume":"25","author":"Stewart","year":"2002","journal-title":"Eval Health Prof"},{"issue":"4","key":"R90-1-20210207","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1086\/499352","article-title":"Risk assessment and treatment of low-risk patients with febrile neutropenia.","volume":"42","author":"Kern","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R91-1-20210207","first-page":"19","article-title":"Systemic inflammatory response syndrome.","volume":"1-","author":"Burdette","year":"2010","journal-title":"eMedicine Critical Care"},{"issue":"6","key":"R92-1-20210207","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.101.6.1644","article-title":"Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCPSCCM Consensus Conference Committee. American College of Chest PhysiciansSociety of Critical Care Medicine.","volume":"101","author":"Bone","year":"1992","journal-title":"Chest"},{"issue":"6","key":"R93-1-20210207","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","article-title":"Risk models for predicting chemotherapy-induced neutropenia.","volume":"10","author":"Lyman","year":"2005","journal-title":"Oncologist"},{"issue":"6","key":"R95-1-20210207","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/10245330701384237","article-title":"Predictive factors of septic shock and mortality in neutropenic patients.","volume":"12","author":"Ramzi","year":"2007","journal-title":"Hematology"},{"issue":"6","key":"R96-1-20210207","doi-asserted-by":"crossref","first-page":"453","DOI":"10.47102\/annals-acadmedsg.V39N6p453","article-title":"Prospective audit of febrile neutropenia management at a tertiary university hospital in Singapore.","volume":"39","author":"Jin","year":"2010","journal-title":"Annals Academy of Medicine Singapore"},{"issue":"11","key":"R98-1-20210207","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/emj.2008.064865","article-title":"Predicting the complicated neutropenic fever in the emergency department.","volume":"26","author":"Moon","year":"2009","journal-title":"Emergency Medicine Journal"},{"key":"R100-1-20210207","first-page":"95","article-title":"The lung in the immunocompromised patient. Infectious complications part 1.","volume":"66","author":"Baughman","year":"1999","journal-title":"Respir Physiol"},{"issue":"2","key":"R101-1-20210207","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/1097-0142(19830715)52:2<325::AID-CNCR2820520223>3.0.CO;2-I","article-title":"Unexplained pulmonary infiltrates in the compromised patient an invasive investigation in a consecutive series.","volume":"52","author":"Canham","year":"1983","journal-title":"Cancer"},{"issue":"2","key":"R102-1-20210207","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.1992.10.2.316","article-title":"Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule.","volume":"10","author":"Talcott","year":"1992","journal-title":"J Clin Oncol"},{"issue":"1","key":"R103-1-20210207","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0002-9343(82)90594-0","article-title":"Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia.","volume":"72","author":"Pizzo","year":"1982","journal-title":"The American Journal of Medicine"},{"issue":"2","key":"R104-1-20210207","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1201-9712(99)90019-X","article-title":"Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin b in the treatment of fungal infections in cancer patients: A review.","volume":"3","author":"Viscoli","year":"1999","journal-title":"Int J Infect Dis"},{"issue":"3","key":"R105-1-20210207","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.critrevonc.2010.03.008","article-title":"Febrile neutropenia: a critical review of the initial management.","volume":"78","author":"Klastersky","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"R106-1-20210207","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0002-9343(97)00136-8","article-title":"Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor.","volume":"103","author":"Francois","year":"1997","journal-title":"The American Journal of Medicine"},{"issue":"2","key":"R107-1-20210207","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/jinf.2001.0798","article-title":"Clinical characteristics and therapeutic outcome of patients with febrile neutropenia who present in shock: need for better strategies.","volume":"42","author":"Malik","year":"2001","journal-title":"J Infect"},{"issue":"3","key":"R108-1-20210207","first-page":"245","article-title":"Thrombocytopenia in sepsis: a predictor of mortality in the intensive care unit.","volume":"34","author":"Lee","year":"1993","journal-title":"Singapore Med J"},{"issue":"12","key":"R109-1-20210207","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1200\/JCO.1990.8.12.1998","article-title":"Early hospital discharge of children with cancer treated for fever and neutropenia: identification and management of the low-risk patient.","volume":"8","author":"Mullen","year":"1990","journal-title":"J Clin Oncol"},{"issue":"1","key":"R110-1-20210207","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0022-3476(05)82536-3","article-title":"Hematologic predictors of bone marrow recovery in neutropenic patients hospitalized for fever: Implications for discontinuation of antibiotics and early discharge from the hospital.","volume":"121","author":"Griffin","year":"1992","journal-title":"The Journal of Pediatrics"},{"issue":"3","key":"R111-1-20210207","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/annonc\/mdj092","article-title":"Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis.","volume":"17","author":"Lalami","year":"2006","journal-title":"Ann Oncol"},{"issue":"1","key":"R112-1-20210207","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/annonc\/mdq332","article-title":"Predicting the duration of chemotherapy-induced neutropenia: new scores and validation.","volume":"22","author":"Matias","year":"2011","journal-title":"Ann Oncol"},{"issue":"3","key":"R113-1-20210207","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1081\/CNV-120001186","article-title":"Empirical oral antibiotic therapy for low risk febrile cancer patients with neutropenia.","volume":"20","author":"Koh","year":"2002","journal-title":"Cancer Invest"},{"issue":"4","key":"R114-1-20210207","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/sj.leu.2403270","article-title":"Incidence and prognostic value of respiratory events in acute leukemia.","volume":"18","author":"Chaoui","year":"2004","journal-title":"Leukemia"},{"issue":"1","key":"R115-1-20210207","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10156-011-0283-5","article-title":"Identifying risk factors for refractory febrile neutropenia in patients with lung cancer.","volume":"18","author":"Fujita","year":"2012","journal-title":"Journal of Infection and Chemotherapy"},{"issue":"6","key":"R116-1-20210207","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0196-6553(97)90067-5","article-title":"Nosocomial infections in an oncology intensive care unit.","volume":"25","author":"Velasco","year":"1997","journal-title":"Am J Infect Control"},{"issue":"4","key":"R117-1-20210207","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1445-5994.1997.tb02199.x","article-title":"Low-risk febrile neutropenia in a medical oncology unit.","volume":"27","author":"Leong","year":"1997","journal-title":"Aust N Z J Med"},{"issue":"2","key":"R118-1-20210207","first-page":"303","article-title":"Factors influencing in-hospital length of stay and mortality in cancer patients suffering from febrile neutropenia.","volume":"9","author":"Lal","year":"2008","journal-title":"Asian Pac J Cancer Prev"},{"issue":"7","key":"R119-1-20210207","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-008-0487-7","article-title":"Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.","volume":"87","author":"Baskaran","year":"2008","journal-title":"Ann Hematol"},{"issue":"8","key":"R120-1-20210207","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s100960050345","article-title":"Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia.","volume":"18","author":"Gonzalez-Barca","year":"1999","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"7","key":"R122-1-20210207","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00520-008-0561-7","article-title":"Infective and thrombotic complications of central venous catheters in patients with hematological malignancy: prospective evaluation of nontunneled devices.","volume":"17","author":"Worth","year":"2009","journal-title":"Support Care Cancer"},{"key":"R123-1-20210207","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1007\/s00277-003-0769-z","article-title":"Central venous catheter (CVC)-related infections in neutropenic patients.","volume":"82","author":"Fatkenheuer","year":"2003","journal-title":"Ann Hematol"},{"issue":"1","key":"R124-1-20210207","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical practice guidelines for the diagnosis and management of intravascular catheterrelated infection: 2009 Update by the Infectious Diseases Society of America.","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"11","key":"R125-1-20210207","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/bjc.2011.385","article-title":"Androgen deprivation therapy as adjuvantneoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments.","volume":"105","author":"Payne","year":"2011","journal-title":"Br J Cancer"},{"issue":"8","key":"R126-1-20210207","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/sj.bjc.6600886","article-title":"Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future.","volume":"88","author":"Riley","year":"2003","journal-title":"Br J Cancer"},{"issue":"25","key":"R127-1-20210207","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJM200006223422507","article-title":"Randomized, controlled trials, observational studies, and the hierarchy of research designs.","volume":"342","author":"Concato","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"R128-1-20210207","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/emj.20.1.54","article-title":"Observational research methods. research design II: cohort, cross sectional, and case-control studies.","volume":"20","author":"Mann","year":"2003","journal-title":"Emergency Medicine Journal"},{"issue":"4","key":"R129-1-20210207","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5","article-title":"What do we mean by validating a prognostic model?","volume":"19","author":"Altman","year":"2000","journal-title":"Stat Med"}],"container-title":["JBI Library of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01583928-201210400-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:53:58Z","timestamp":1786452838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01583928-201210400-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":110,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.11124\/jbisrir-2012-31","relation":{},"ISSN":["1838-2142"],"issn-type":[{"value":"1838-2142","type":"print"}],"subject":[],"published":{"date-parts":[[2012]]}}}